Here we examined the addition of intensity-modulated @entity236 ( @entity236 ) delivered using a linear accelerator to a myeloablative chemotherapy conditioning regimen before allogeneic hematopoietic stem cell transplantation (HSCT). In this phase I study, we enrolled 14 @entity1 with high-risk @entity1583 who received escalating doses of @entity236 at 3  Gy (n  =  3), 6  Gy (n  =  3), 9  Gy (n  =  6), and 12  Gy (n  =  2) in combination with intravenous (i.v.) @entity3118 160  mg/m(2) and targeted @entity1863 (area under the curve, 4800   M*minute). Peripheral blood mobilized stem cells were obtained from HLA-matched related (n  =  9) or unrelated (n  =  4) or 1 antigen-mismatched unrelated (n  =  1) donors. All @entity1 rapidly engrafted and recovered their immune cells. Overall, Bearman extrahematologic @entity137 were limited to grades 1 or 2, with @entity3136 grade 1 in 64% and grade 2 in 36% of the @entity1 . With a median follow-up of 1126  days (range, 362 to 1469) for living @entity1 , the overall survival was 50% and relapse-free survival was 43%. Of 7 deaths, 3 were due to relapse and 4 to transplantation-related complications. We conclude that 9  Gy @entity236 can be combined with myeloablative chemotherapy in the design of new preparative regimens for HSCT. This study was registered at clinicaltrials.gov as NCT00988013.

Combination of Linear Accelerator-Based Intensity-Modulated Total Marrow Irradiation and Myeloablative XXXX / @entity1863 : A Phase I Study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['oral mucositis'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancies'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan'] @entity236 :: ('MESH:D001855', 'Disease') :: ['total marrow irradiation', 'TMI']
@entity3118 :: (MESH:C024352,Chemical) :: ['Fludarabine']
